Sensei Biotherapeutics Statistics
Share Statistics
Sensei Biotherapeutics has 25.21M
shares outstanding. The number of shares has increased by 0.28%
in one year.
| Shares Outstanding | 25.21M |
| Shares Change (YoY) | 0.28% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 9.34% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 25,379 |
| FTD / Avg. Volume | 0.91% |
Short Selling Information
The latest short interest is 398.14K, so 1.58% of the outstanding
shares have been sold short.
| Short Interest | 398.14K |
| Short % of Shares Out | 1.58% |
| Short % of Float | 2.37% |
| Short Ratio (days to cover) | 3.48 |
Valuation Ratios
The PE ratio is -0.41 and the forward
PE ratio is -0.44.
Sensei Biotherapeutics's PEG ratio is
0.25.
| PE Ratio | -0.41 |
| Forward PE | -0.44 |
| PS Ratio | 0 |
| Forward PS | 0.8 |
| PB Ratio | 0.32 |
| P/FCF Ratio | -0.5 |
| PEG Ratio | 0.25 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Sensei Biotherapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.7,
with a Debt / Equity ratio of 0.1.
| Current Ratio | 7.7 |
| Quick Ratio | 7.7 |
| Debt / Equity | 0.1 |
| Debt / EBITDA | -0.12 |
| Debt / FCF | -0.15 |
| Interest Coverage | -362.38 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-2,154,071.43 |
| Employee Count | 14 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -78.67% in the
last 52 weeks. The beta is 0.19, so Sensei Biotherapeutics's
price volatility has been higher than the market average.
| Beta | 0.19 |
| 52-Week Price Change | -78.67% |
| 50-Day Moving Average | 0.39 |
| 200-Day Moving Average | 0.49 |
| Relative Strength Index (RSI) | 38.65 |
| Average Volume (20 Days) | 2,789,216 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -32.61M |
| Net Income | -30.16M |
| EBITDA | -32.61M |
| EBIT | -30.25M |
| Earnings Per Share (EPS) | -1.2 |
Full Income StatementBalance Sheet
The company has 9.99M in cash and 3.85M in
debt, giving a net cash position of 6.15M.
| Cash & Cash Equivalents | 9.99M |
| Total Debt | 3.85M |
| Net Cash | 6.15M |
| Retained Earnings | -262.05M |
| Total Assets | 38.27M |
| Working Capital | 30.45M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -24.67M
and capital expenditures -146K, giving a free cash flow of -24.82M.
| Operating Cash Flow | -24.67M |
| Capital Expenditures | -146K |
| Free Cash Flow | -24.82M |
| FCF Per Share | -0.99 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
